ResMed (RMD) director reports 487-share sale, 76.449-share tax disposal

Rhea-AI Filing Summary

ResMed Inc. director Jan De Witte reported stock transactions in company shares. On 11/11/2025, he sold 487 shares of ResMed common stock at $250.25 per share under a pre-arranged Rule 10b5-1 trading plan adopted on Feb 03, 2025. On the same date, 76.449 shares were disposed of to the issuer to cover tax withholding tied to the vesting of previously granted restricted stock units from 11/20/2024. After these transactions, he directly owned 5,242 shares of ResMed common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

De Witte Jan

(Last) (First) (Middle)

9001 SPECTRUM CENTER BLVD.

C/O RESMED INC

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ReMed Common Stock	11/11/2025		S(1)		487	D	$250.25	5,319	D
ReMed Common Stock	11/11/2025		F(2)		76.449	D	$250.1	5,242	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted Feb 03, 2025.

2. Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/20/2024.

	Jan De Witte, director	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ResMed (RMD) report for Jan De Witte?

On 11/11/2025, director Jan De Witte reported selling 487 shares of ResMed common stock at $250.25 per share and disposing of 76.449 shares for tax withholding.

How many ResMed (RMD) shares does Jan De Witte own after these transactions?

Following the reported transactions on 11/11/2025, Jan De Witte directly owned 5,242 shares of ResMed common stock.

Were the ResMed (RMD) share sales under a Rule 10b5-1 trading plan?

Yes. The sale of 487 shares on 11/11/2025 was conducted under a Rule 10b5-1 plan that Jan De Witte adopted on Feb 03, 2025.

Why were 76.449 ResMed (RMD) shares disposed of in the Form 4?

The 76.449 shares were disposed of to the issuer for tax withholding related to the vesting of restricted stock units that were granted on 11/20/2024.

What is Jan De Witte’s role at ResMed (RMD)?

Jan De Witte is reported as a director of ResMed Inc. in the filing.

Was this Form 4 filing made by more than one reporting person for ResMed (RMD)?

No. The filing indicates it is a Form filed by one reporting person, covering transactions by Jan De Witte only.